The Asian Fund for Cancer Research and the US Chinese Anti-Cancer Association jointly awarded six outstanding Chinese cancer researchers in the early stages of their careers with the 2018 USCACA-AFCR Young Investigator Award. Scholars received a certificate for the Award and a cheque in the amount of U.S. $1,000 in a Saturday, 17 November 2018, ceremony in Tianjin, being held during the Third International Convention on Cancer Translational Research.
Chinese researchers and physicians are being increasingly recognized for making significant contributions to advance biomedical science, including cancer research in China and throughout the world. Since 2010, AFCR has annually joined with USCACA in selecting, recognizing and rewarding outstanding young individuals for their excellence in basic or clinical cancer research. The ultimate goal of the USCACA-AFCR Young Investigator Award is to expedite novel cancer drug development by stimulating the translation of lab discoveries to novel cancer treatments, fostering collaborations in clinical cancer drug development and sharing best practices and knowledge between China and the United States.
The recent awardees are Xinjian Li, Ph.D., Chinese Academy of Sciences Key Laboratory of Infection and Immunity; Dongsheng Yue, Ph.D., Tianjin Medical University Cancer Institute and Hospital; Yanru Wang, M.D., Ph.D., Zhujiang Hospital Southern Medical University; Xingding Zhang, Ph.D., Sun Yat-Sen University; Puyu Shi, M.D., First Affiliated Hospital of Xi’An Jiaotong University; and Wantong Song, Ph.D., Changchun Institute of Applied Chemistry.